Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 17 March 2023 Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the first participant has been dosed in the U.S. in the Company’s Phase 2 clinical trial of ATH434 in…
Cynata Adds New Sites for DFU Clinical Trial
Posted: 17 March 2023 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that three additional clinical sites have opened for recruitment in the ongoing clinical trial of CYP-006TK in patients with diabetic foot…
Smart nanotechnology for more accurate delivery of insulin
Posted: 16 March 2023 More efficient and longer lasting glucose-responsive insulin that eliminates the need for people with type 1 diabetes to measure their glucose levels could be a step closer thanks to a Monash University-led project. Published…
Women-led startup innovations in pregnancy monitoring, clinical trials supported by $750,000 University investment
Posted: 16 March 2023 The University of Melbourne will provide pre-seed investment to support two innovative female-founded healthcare startups, innovative at-home pregnancy monitoring start-up Kali Healthcare, and clinical trial participant recruitment start-up Torch Recruit. Kali Healthcare, co-founded by…
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Posted: 16 March 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”)…
Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
Posted: 16 March 2023 Pfizer Inc. and BioNTech SE announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
Extension for project tackling antimicrobial resistance in PNG
Posted: 15 March 2023 A major project tackling antimicrobial resistance (AMR) in Papua New Guinea has been extended until December 2023. The Fleming Fund Country Grant – Papua New Guinea (PNG) is led by Burnet Institute working in close collaboration…
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
Posted: 15 March 2023 Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its U.S. presence and establishing a corporate presence on the West Coast with new offices in South…
Optiscan Platform Highly Accurate for Oral Cancer Diagnosis
Posted: 15 March 2023 Optiscan Imaging Limited is pleased to announce interim results of its oral imaging study conducted by Professor Farah and his team at the Australian Centre for Oral Oncology Research & Education. Data analysed as…
Back-to-back Studies Validate geneType Breast Cancer Risk Test
Posted: 14 March 2023 Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment…
FDA Approves First Treatment for Rett Syndrome
Posted: 14 March 2023 Neuren Pharmaceuticals announced that its North America partner Acadia Pharmaceuticals received US Food and Drug Administration (FDA) approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years…
Imagion Funding Update
Posted: 9 March 2023 Imagion Biosystems, a company dedicated to improving healthcare through the early detection of cancer, announced an entitlement offer to its shareholders seeking to raise up to $2.4 million as well as a funding facility…
